# Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets

> **NCT03056703** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 38 (estimated)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Acetylsalicylic acid (Aspirin, BAY1019036)
- **DRUG:** Acetylsalicylic acid (Aspirin, BAY1019036)

## Key facts

- **NCT ID:** NCT03056703
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03056703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03056703, "Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03056703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*